FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trial

Hebbar, M.; Chibaudel, B; Andre, T; Mineur, L; Smith, D.; Louvet, C.; Dutel, J.L.; Ychou, M; Legoux, J.L.; Mabro, M.; Faroux, R; Auby, D.; Brusquant, D; Khalil, A.; Truant, S; Hadengue, A; Dalban, C; Gayet, B; Paye, F; Pruvot, F.R.; Bonnetain, F; Taieb, J.; Brucker, P.; Landi, B; Flesch, M; Carola, E; Martin, P.; Vaillant, E.; de Gramont, A

doi:10.1093/annonc/mdu539

Record: found
Abstract: not found
Article: not found

FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trial

Author(s): M. Hebbar , B. Chibaudel , T. André , L. Mineur , D. Smith , C. Louvet , J.L. Dutel , M. Ychou , J.L. Legoux , M. Mabro , R. Faroux , D. Auby , D. Brusquant , A. Khalil , S. Truant , A. Hadengue , C. Dalban , B. Gayet , F. Paye , F.R. Pruvot , F. Bonnetain , J. Taieb , P. Brucker , B. Landi , M. Flesch , E. Carola , P. Martin , E. Vaillant , A. de Gramont

Publication date Created: February 2015

Publication date (Print): February 2015

Journal: Annals of Oncology

Publisher: Oxford University Press (OUP)

Read this article at

ScienceOpenPublisher

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Perioperative FOLFOX4 (oxaliplatin plus 5-fluorouracil/leucovorin) chemotherapy is the current standard in patients with resectable metastases from colorectal cancer (CRC). We aimed to determine whether a sequential chemotherapy with dose-dense oxaliplatin (FOLFOX7) and irinotecan (FOLFIRI; irinotecan plus 5-fluorouracil/leucovorin) is superior to FOLFOX4. The chemotherapy timing was not imposed, and was perioperative or postoperative.